Effects of vitamin E and HMG-CoA reductase inhibition on cholesteryl ester transfer protein and lecithin-cholesterol acyltransferase in hypercholesterolemia

Coronary Artery Disease

Volumn 9, Issue 5, 1998, Pages 257-264

  Napoli, Claudio ^a,e   Leccese, Maurizio ^c   Palumbo, Giuseppe ^a   De Nigris, Filomena ^a   Chiariello, Paola ^a   Zuliani, Patrizia ^a   Somma, Pasquale ^a   Di Loreto, Mario ^a   De Matteis, Carmine ^d   Cacciatore, Francesco ^a   Abete, Pasquale ^a   Liguori, Antonio ^b   Chiariello, Massimo ^a   D'Armiento, Francesco P ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Pellegrini Hospital   (Italy)

^c Cardiology Unit   (Italy)

^d S Felice Hospital   (Italy)

^e FACA   (Italy)

Author keywords

Antioxidants; Atherosclerosis; CETP; Hypercholesterolemia; LCAT; Oxygen radicals; Pravastatin; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PRAVASELECT; PRAVASTATIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 7344251775     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199809050-00003     Document Type: Article

References (51)

1. Gordon T, Castelli WP, Hyortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Heart Study. Am J Med 1977; 62:707-714.
2. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91:2488-2496.
3. Fielding CJ. Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36:211-228.
4. Bruce C, Tall AR. Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis. Curr Opin Lipidol 1995; 6:306-311.
5. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993; 34:1255-1274.
6. Van Gent T, Van Tol A. Automated gel permeation chromatography of plasma lipoproteins by preparative fast protein liquid chromatography. J Chromatogr 1990; 525:433-438.
7. Cheung MC, Wolf AC.,Lum KD, Tollefson JH, Albers JJ. Distribution and localisation of lecithin:cholesterol acyl transferase and cholesteryl ester transfer protein activity in A-I-containing lipoproteins. J Lipid Res 1986; 27:1135-1142.
8. Groener JEM, Van Ramshorst EM, Katan MB, Mensink RP, Van Tol A. Diet-induced alteration in the activity of plasma lipid transfer protein in normolipidemic human subjects. Atherosclerosis 1991; 87:221-226.
9. Hayek T, Masucci-Magoulas L, Jiang X. Decreased early atherosclerotic lesions in hypertrigtyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 1995; 96:2071-2074.
10. Hoeg JM, Brewer HB. 3-Hydroxy-3-methylglutaryl-CoA-reductase inhibitors in the treatment of hypercholesterolemia. JAMA 1987; 258:3532-3536.
11. Walker JF. Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia. Am J Cardiol 1990; 65:19F-22F.
12. Ahnadi CE, Berthezene F, Ponsin G. Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. Atherosclerosis 1993; 99:219-228.
13. Zhao SP, Smelt AHM, Van den Maagdenberg AMJM, Van Tol A, Vroom TFFP, Gevers Leuven JA, et al. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2 (Arg158→Cys), E3-Leiden, and E2 (Lys146→Gln), and effects of treatment with simvastatin. Arterioscler Thromb 1994; 14:1705-1716.
14. Cheung MC, Austin MA, Moulin P, Wolf AC, Cryer D, Knopp RH. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis 1993; 102:107-119.
15. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996; 20:707-727.
16. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88:1785-1792.
17. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272:20963-20966.
18. Napoli C. Low density lipoprotein oxidation and atherogenesis. From experimental models to clinical studies. G Ital Cardiol 1997; 27:1302-1314.
19. Napoli C, D'Armiento FP, Mancini FP, Witztum JL, Palumbo G, Palinski W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimai accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997; 100:2680-2690.
20. Parthasarathy S, Barnett J, Fong LJ. High-density lipoprotein inhibits the oxidative modification of low density lipoprotein. Biochim Biophys Acta 1990; 1044:275-283.
21. Chen C, Loo G. Effect of peroxyl radicals on lecithin/cholesterol acyltranferase activity in human plasma. Lipids 1995; 30:627-631.
22. Nakaya N, Homma Y, Tamaky H, Goto Y. The effects of CS-514, a new inhibitor of HMG CoA reductase, on serum lipids in healthy volunteers. Atherosclerosis 1986; 61:125-128.
23. WHO Memorandum. Classification of hyperlipoproteinemias. Circulation 1975; 45:501-522.
24. Hennekens CH, Gaziano JM. Antioxidants and heart disease. Epidemiology and clinical evidence. Clin Cardiol 1993; 16:110-115.
25. Napoli C, Mancini FP, Corso G, Malorni A, Crescenzi E, Palumbo G. A simple and rapid purification procedure minimizes spontaneous oxidative modifications of low-density lipoprotein and lipoprotein(a). J Biochem 1997; 121:1096-1101.
26. Napoli C, Postiglione A, Triggiani M, Corso G, Palumbo G, Carbone V, et al. Oxidative structural modifications of low density lipoproteins in homozygous familial hypercholesterolemia. Atherosclerosis 1995; 118:259-273.
27. Napoli C, Chianello M, Palumbo G, Ambrosio G. Calcium channel blockers inhibit human low density lipoprotein oxidation by oxygen radicals. Cardiovasc Drug Ther 1996; 10:417-424.
28. Napoli C, Ambrosio G, Scarpato N, Corso G, Palumbo G, D'Armiento FP, et al. Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia. Am Heart J 1997; 133:585-595.
29. Napoli C, Paternò R, Faraci FM, Taguchi H, Postiglione A, Heistad DD. Mildly oxidized low-density lipoprotein impairs responses of carotid but not basilar artery. Stroke 1997; 28:2266-2272.
30. Albers JJ, Adolphson JL. Comparison of commercial kits for apoprotein A and apoprotein B with standardized apoprotein A and B radioimmunoassays performed at the Northwest Lipid Research Center. J Lipid Res 1988; 29:102-108.
31. Lowry OH, Rosebrough HJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193:265-275.
32. Glomset JA, Wright JL. Some properties of cholesterol esterifying enzyme in human plasma. Biochim Biophys Acta 1964; 89:266-276.
33. Groener JEM, Pelton RW, Kostner GM. Improved estimation of cholesteryl ester transfer/exchange activity in serum or plasma. Clin Chem 1986; 32:283-286.
34. Crepaldi G, Baggio G, for the Italian Multicenter Pravastatin Study I. Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. Arch Intern Med 1990; 151:146-152.
35. Hunninghake DB, Knopp RH, Schonfeld G. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. Atherosclerosis 1990; 85:81-89.
36. Napoli C, Lepore S, Ambrosio G, Chiariello M. Evaluation of pravastatin in single therapy or in association with gemfibrozil in hypercholesterolemia. Cardiologia 1992; 37:761-768.
37. Malacco E, Magni A, Scandiani L, Casini A, D'ascia C, Napoli C, for the Italian Multicenter Study. Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. Drug Invest 1994; 7:331-339.
38. Napoli C, Lepore S, Chiariello P, Condorelli M, Chiariello M. Long-term treatment with pravastatin alone and in combination with gemfibrozil in familial type IIb hyperlipoproteinemia or combined hyperlipidemia. J Cardiovasc Pharmacol Ther 1997; 2:17-26.
39. Jiang XC, Masucci-Magoulas L, Mar J. Down-regulation of messenger RNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein - mechanism to explain accumulation of lipoprotein-B particles. J Biol Chem 1993; 268:27406-27412.
40. Masucci-Magoulas L, Plump A, Jiang XC, Walsh A, Breslow JL, Tall AR. Profound induction of hepatic cholesteryl ester tarnsfer protein transgene expresssion in apolipoprotein E and low density lipoprotein receptor gene knockout mice - a novel mechanism signals changes in plasma cholesterol levels. J Clin Invest 1996; 97:154-161.
41. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-154.
42. Stafforini DM, Zimmermann TM, McIntyre TM, Prescott SM. The platelet activating factor acetylhydrolase from human plasma prevents oxidative modification of low density lipoprotein. Trans Am Assoc Phys 1993; 106:44-63.
43. Ambrosio G, Oriente A, Napoli C, Palumbo G, Chiariello P, Marone G, et al. Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor. J Clin Invest 1994; 93:2045-2054.
44. McPherson R, Hogue M, Milne RW, Tall AR, Marcel YL. Increase in plasma cholesteryl ester transfer protein during probucol treatment. Relation to changes in high density lipoprotein composition. Arterioscler Thromb 1991; 11:476-481.
45. Franceschini G, Chiesa G, Sirton CR. Probucol increases cholesteryl ester transfer protein activity in hypercholesterolaemic patients. Eur J Clin Invest 1991; 21:384-388.
46. Homma Y, Kobayashi T, Yamaguchi H, Sakane H, Ozawa H, Matsuda M, et al. Decrease of plasma large, light LDL (LDL1), HDL2 and HDL3 levels with concomitant increase of cholesteryl ester transfer protein (CETP) activity by probucol in type II hyperlipoproteinemia. Artery 1993; 20: 1-18.
47. Bagdade JD, Stein E, Ritter MC. Probucol normalizes cholesteryl ester transfer in IDDM. Diabetes Care 1995; 18:1341-1346.
48. Tonstad S, Aksnes L. Fat soluble vitamin levels in familial hypercholesterolemia. J Pediatr 1997; 130:274-280.
49. Muldoon MF, Kritchevsky SB, Evans RW, Kagan VE. Serum total antioxidant activity in relative hypo- and hypercholesterolemia. Free Radic Res 1996; 25:239-245.
50. Human JA, Ubbink, JB, Jerling JJ, Delport R, Vermaak WJ, Worster HH, et al. The effects of simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolemia. Clin Chim Acta 1997; 263:67-77.
51. Albers JJ, Chen CH, Adolphson JL. Lecithin:cholesterol acyltransferase (LCAT) mass: its relationship to LCAT activity and cholesterol esterification rate. J Lipid Res 1981; 22:1206-1213.